Short interest for Mentor Capital gives investors a sense of the degree to which investors are betting on the decline of Mentor Capital's stock. Short interest data is updated every two weeks.

Mentor Capital Stock (OTC:MNTR), Short Interest Report

Mentor Capital Inc general business operations are intended to provide management consultation and headquarters functions, especially with regard to funding, accounting, and audits, for its majority-owned subsidiaries, which makes up most of its holdings. The Company has determined that there are currently two reportable segments: 1) the historic residual medical operations segment and 2) the Company's energy segment. The historic residual medical operations segment includes the cost basis of its former membership interests of Electrum, the former contractual interest in the Electrum legal recovery, the settlement payments receivable from G Farma and its co-defendants. The classic energy segment consist of the Company's operations and investment in the classic energy space.

Long Ideas

News

Penny Stocks

Insider Trades

Pre-Market Outlook

Markets

Trading Ideas

INTZ

MNTR

PRKA

RAIN

The Dow Jones closed slightly higher on Friday. When insiders purchase or sell shares, it indicates their confidence or concern around the company&#39;s prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision.

Rain Oncology And 3 Other Stocks Under $1 Insiders Are Buying

Cannabis

BHNGF

CWBHF

The size of the global cannabis-infused edible products market is anticipated to grow by $25.27 billion from 2020 to 2025, according to Technavio report. Moreover, the growth momentum of the market will accelerate at a CAGR of 21.74% during the forecast period (2021-2025).

Technavio Forecasts Cannabis-Infused Edible Products Market Size To Grow By $25.27B

Small Cap

AQSP

CBDS

CNBS

CRLBF

CURALEAF HLDGS INC by Curaleaf Hldgs Inc.

CURLF

CXXIF

EVGN

HLIX

HRVSF

MJNA

TCNNF

THCX

TLRY

YCBD

YOLO

CSE:HBOR

CSE:CL

CSE:CURA

CSE:TRUL

TSXV:PCLO

PCLFO

CSE:HARV

TSX:ACB

CSE:CXXI

Cannabis stocks outperformed the S&amp;P 500 this week. Over the last five trading days:

The Week In Cannabis: Stocks Outperform S&amp;P, Mexico Moves Forward, Earnings, And More

MENTOR CAPITAL INC by Mentor Capital, Inc.

Mentor Capital Inc

The Dow Jones closed slightly higher on Friday. When insiders purchase or sell shares, it indicates their confidence or concern around the company&#39;s prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision.
Below is a look at a few recent notable insider transactions for penny stocks. For more, check out <a href="https://www.benzinga.com/sec/insider-trades/"> Benzinga&#39;s insider transactions </a> platform.
<h3>Parks! America </h3>
<ul>
<li>The Trade: Parks! America, Inc. (OTC: <a class="ticker" href="https://www.benzinga.com/stock/prka#OTC">PRKA</a>) Director Charles Kohnen <a href="https://www.benzinga.com/quote/PRKA/analyst-ratings"> acquired a total of 100,000 shares </a> an average price of $0.40. To acquire these shares, it cost around $40,000.</li>
<li>What&rsquo;s Happening: Total revenues for the fiscal quarter ended July 2, 2023 fell to $2.85 million, from $3.64 million for the fiscal quarter ended July 3, 2022.</li>
<li>What Parks! America Does: Parks! America Inc through its subsidiaries involved in the business of acquiring, developing and operating local and regional theme parks and attractions in the United States.</li>
</ul>
<h3>Rain Oncology</h3>
<ul>
<li>The Trade: Rain Oncology Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/rain#NASDAQ">RAIN</a>) 10% owner Tang Capital Partners LP <a href="https://www.benzinga.com/sec/insider-trades/"> acquired a total of 284,145 shares </a> at an average price of $0.98. To acquire these shares, it cost around $279,030.</li>
<li>What&rsquo;s Happening: Rain Oncology posted a wider-than-expected quarterly loss.</li>
<li>What Rain Oncology Does: Rain Oncology Inc is a late-stage precision oncology company developing therapies that target oncogenic drivers for which it is able to genetically select patients it believes will likely benefit.</li>
</ul>
Check This Out: <a href="https://www.benzinga.com/trading-ideas/long-ideas/23/10/35239191/top-5-tech-and-telecom-stocks-that-may-explode-this-month"> Top 5 Tech And Telecom Stocks That May Explode This Month </a>
<h3>Intrusion </h3>
<ul>
<li>The Trade: Intrusion Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/intz#NASDAQ">INTZ</a>) 10% owner Raymond T Hyer <a href="https://www.benzinga.com/sec/insider-trades/"> acquired a total of 306,800 shares </a> at an average price of $0.33. The insider spent $101,717 to buy those shares.</li>
<li>What&rsquo;s Happening: Intrusion was awarded a $5 million multi-year shield agreement with a telecommunications provider.</li>
<li>What Intrusion Does: Intrusion Inc is a cybersecurity company based in Plano, Texas. It is engaged in developing, marketing and supporting a group of entity identification, high-speed data mining, cybercrime and persistent threat detection products.</li>
</ul>
<h3>Mentor Capital </h3>
<ul>
<li>The Trade: Mentor Capital, Inc. (OTC: <a class="ticker" href="https://www.benzinga.com/stock/mntr#OTC">MNTR</a>) Director Lori Stansfield <a href="https://www.benzinga.com/quote/SPWH/analyst-ratings"> acquired a total of 37,418 shares </a> at an average price of $0.07. The insider spent around $2,713.</li>
<li>What&rsquo;s Happening: The company&rsquo;s stock gained around 38% year-to-date.</li>
<li>What Mentor Capital Does: Mentor Capital Inc acquires and provides liquidity for medical and social use cannabis companies. The company is operating an acquisition and investment business.</li>
</ul>
&nbsp;
Don&rsquo;t forget to check out our <a href="https://www.benzinga.com/premarket/"> premarket coverage here </a>

The size of the global cannabis-infused edible products market is anticipated to grow by $25.27 billion from 2020 to 2025, according to Technavio report. Moreover, the growth momentum of the market will accelerate at a CAGR of 21.74% during the forecast period (2021-2025).
What are the Some of the Topics Covered in this Report?
<ul>
<li>
Overview of the Market
</li>
<li>
Market Sizing
</li>
<li>
Five Forces Analysis
</li>
<li>
Market Segmentation
</li>
<li>
Factors Impacting Market Growth
</li>
<li>
Vendor Analysis
</li>
</ul>
What are the Factors Driving the Growth of the Cannabis-infused Edible Products Market?
The growth of the cannabis-infused edible products market will be driven by the growing social acceptance of cannabis. The perception of cannabis has changed across several countries. The market has attracted new vendors and large investors. The rising popularity of recreational marijuana has provided traction to the global legal cannabis market.
What are the Trends Supporting the Growth of the Cannabis-infused Edible Products Market?
The increasing number of countries decriminalizing cannabis is a key trend that will support the growth of the cannabis-infused edible products market. Portugal became the first country in the world to legalize the use of all drugs, including marijuana. Canada has legalized the use of marijuana for recreational and medical purposes. Other countries that have legalized the use of marijuana for medical purposes include Ireland, Jamaica, Australia, Germany&nbsp;and South Africa.
Which are the Major Vendors Operating in the Cannabis-infused Edible Products Market?
According to Technavio, the major vendors operating in the cannabis-infused edible products market include Bhang Corp. (OTCQB: <a class="ticker" href="https://www.benzinga.com/stock/bhngf#OTCQB">BHNGF</a>), Botanic Lab, Cannabinoid Creations, CHARLOTTES WEB (OTCQX: <a class="ticker" href="https://www.benzinga.com/stock/cwbhf#OTCQX">CWBHF</a>), Gr&ouml;n Confections, Kats Botanicals, Kiva Brands Inc., Lulu Group International, Medix CBD, and Mentor Capital Inc. (OTCQB: <a class="ticker" href="https://www.benzinga.com/stock/mntr#OTCQB">MNTR</a>) among others.
Is the Market Fragmented or Concentrated?
The cannabis-infused edible products market is fragmented, and the vendors are deploying organic and inorganic growth strategies to compete in the market. The vendors in the market are focusing on launching new and innovative products, a cost-effective production cycle, and developments in the distribution in new and existing markets.
Photo: Courtesy of Technavio

The Week In Cannabis: Stocks Outperform S&P, Mexico Moves Forward, Earnings, And More

<h3>Helix Technologies Reports Strong Quarter &nbsp;</h3>
Helix Technologies&nbsp;Inc. (OTCQB: <a href="http://www.benzinga.com/stock/hlix/">HLIX</a>) <a href="http://www.globenewswire.com/news-release/2020/11/13/2126785/0/en/Helix-Technologies-Releases-Q3-2020-Results-868-Increase-in-Software-Adjusted-EBITDA-Strengthened-Balance-Sheet-Growing-Software-Revenues-and-Client-Numbers-While-Gross-Margin-Grow.html">announced&nbsp;year-to-date and third-quarter results</a>, noting positive adjusted EBITDA in the quarter of $95,000.
Year-to-date revenue jumped 13% from the prior year to $8.8 million, and the company also enhanced its year-to-date gross margin reaching 68%, versus 53% in 2019.
The Denver-based company noted its quarterly software revenue had increased 18% from 2019, reaching $2.8 million.
One important business milestone achieved in the previous period Helix highlighted was its launching of the US&rsquo; first all-electronic medical marijuana patient reciprocity program in New Mexico.
&ldquo;We continue to deliver profitable operations and expand our combined software footprint, which is the largest in the industry, period,&quot; Helix Technologies CEO and executive chair Zachary Venegas said. &quot;Our third consecutive quarter of positive Adjusted EBITDA, and improvement in nearly every operational and financial metric, all done without additional capital, demonstrates to the market that our team continues to set the industry standard. Q3 was truly a pivotal quarter for Helix and in light of recent events we are poised to further expand on our market position into existing as well as newly legalized markets.&quot;
Helix also increased its&nbsp;net client count,&nbsp;delivering one of its&nbsp;strongest quarters&nbsp;in client retention and competitor take-aways, while growing third&nbsp;party revenue, Venegas added.&nbsp;
<h3>Mentor Capital Discloses Quarterly Net Loss </h3>
Investment firm with a primary focus on cannabis and medical marijuana companies, Mentor Capital&nbsp;Inc. (OTCQB: <a href="http://www.benzinga.com/stock/mntr/">MNTR</a>) <a href="http://www.businesswire.com/news/home/20201116005483/en/Mentor-Capital-Reports-3rd-Quarter-2020-10-Q">posted Monday</a> its third-quarter earnings with revenues of $1.23 million versus $1.07 million generated in the same quarter of 2019.
The company also disclosed a net loss of $273,955 or a loss of 1.2 cents per share, which stands against a net loss of $336,816 or a loss of 1.5 cents per share in the third quarter of the prior year.
Furthermore, Mentor Capital reported huge losses from G Farma&rsquo;s default on finance leases and notes receivable, and in the nine months ended Sept. 30, 2019 it had noted bad debt on the finance leases of $739,469 and impairment loss of $1.69 million on its obtained notes receivable from G Farma.
&nbsp;At the end of the reporting quarter, the company achieved a market capitalization of $1.6 million with a price per share of $0.07, which compares to a market capitalization of $2.74 million and a closing of 12 cents per share in the same period of 2019.
In addition, at the end of October, Dr. Robert Mandelkorn acquired Mentor&rsquo;s interest in a Florida-based glaucoma cannabis oil project, GlauCanna, for $31,000.
<h3>Acquired Sales Corp Posts Higher Revenue, Projects Even Stronger Q4</h3>
Cannabinoid investment firm&nbsp;Acquired Sales Corp. (OTCQB: <a href="http://www.benzinga.com/stock/aqsp/">AQSP</a>)&nbsp;<a href="http://www.globenewswire.com/news-release/2020/11/16/2127128/0/en/Publicly-Traded-Cannabis-Company-Acquired-Sales-Corp-Reports-Increased-Sales-and-Positive-Net-Income-in-Third-Quarter.html">reported third-quarter</a>&nbsp;revenue of $1.51 million, up by 19% from the previous quarter.
It has also reported a net income of $95,823, projecting to see an even higher net revenue in the fourth quarter.
&ldquo;So far this quarter, Lifted Made&rsquo;s sales are surging. Under Lifted Made&rsquo;s flagship Urb Finest Flowers brand, our delta 8 THC cartridges and gummies, CBD moon rocks, caviar cones, and our private label products are experiencing a tremendous reception from our distributors and customers,&rdquo; AQSP&nbsp;COO Nicholas Warrender said. &ldquo;We are also developing new and exciting SKUs that are launching throughout the rest of this year and early Q1 2021 that we expect will be picked up by our existing and growing distribution channels throughout the country.&rdquo;
Warrender is also&nbsp;CEO of the subsidiary Lifted Made.&nbsp;The plan is to soon sign a lease of a building in Kenosha, Wisconsin to further expand its space.
AQSP CFO William Jacobs praised the company&rsquo;s achievements, adding:&nbsp;&ldquo;We are very encouraged by the fact that Acquired Sales Corp. has so far survived the pandemic without incurring any new debt other than governmental PPP and EID loans. Moreover, we are proud of the fact that no employees or independent contractors of Acquired Sales Corp. or Lifted Made were laid off or furloughed during the pandemic; in fact, we have added to our workforce.&rdquo;

Earnings

Earnings Update: Helix Touts 'Pivotal Quarter', Mentor Capital Posts Net Loss, Acquired Sales Revenue Jumps